Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures

Sydbank senior analyst Søren Løntoft Hansen expects Genmab to upgrade its total predicted market sales for 2021 after Johnson & Johnson's Q2 sales figures for Darzalex were revealed on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Darzalex sales exceed expectations in second quarter
For subscribers
Genmab surpasses 1,000 employees
For subscribers